Novel Advances in Cancer Detection, New Findings on Sexual Health in Patients With Prostate Cancer to Be Presented at the ASCO Breakthrough Meeting in Japan

For immediate release
July 18, 2023

Contact

Savannah Rogers
571-483-1592

ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) Breakthrough Meeting will convene oncology professionals from around the world in Yokohama, Japan, to explore cutting-edge advances in cancer care technology and innovations that can help transform care for people living with cancer.

Taking place August 3-5 in Yokohama, Japan, ASCO Breakthrough is planned and cohosted by ASCO, the Japan Society of Clinical Oncology, the Japanese Society of Medical Oncology, along with many other collaborating societies in the Asia Pacific region.

More than 160 abstracts will be presented at ASCO Breakthrough. Abstract titles are now available online and the full abstracts will be publicly released on Monday, July 31, at 5:00 PM (ET) at www.asco.org/bkth-abstracts

ASCO BREAKTHROUGH PRESS PROGRAM

The following abstracts will be highlighted in press releases as part of the meeting’s official Press Program:

  • A novel non-invasive multi-target stool DNA methylation assay for early detection of gastrointestinal cancers. (Abstract 41
  • Effects of supervised exercise and self-managed psychosexual therapy on sexual health in men with prostate cancer: A randomized clinical trial. (Abstract 71)
  • Development of an artificial intelligence-based diagnostic system for the detection of abnormal colposcopic findings. (Abstract 82)
  • Clinical validation of a ctDNA-based assay for multi-cancer detection: An interim report from a Vietnamese longitudinal prospective cohort study of 2,795 participants. (Abstract 135)

Authors of the above abstracts will also summarize their findings and be available for questions for reporters covering the meeting on site in Yokohama on Thursday, August 3, and Friday, August 4, of the meeting.

MEDIA RESOURCES 

Media registration: To apply for ASCO media credentials to access embargoed media materials, session livestreams, and on-demand content and/or to register to attend the Meeting in person in Yokohama, please visit ASCO’s Media Headquarters at https://profile.asco.org/media/workflow. Step-by-step instructions are available online

Cancer.Net: Visit ASCO’s lay-friendly website featuring the latest, comprehensive oncologist-approved information about cancer diagnosis, statistics, treatment, survivorship, and more. This trustworthy resource can help ensure your reporting is accurate, informative, and accessible to a wide audience. 

### 

About ASCO: 

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.